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Abstract
Background: Galectin-3 (Gal-3) and active (GTP-bound) K-Ras contribute to the malignant phenotype of many human
tumors by increasing the rate of cell proliferation, survival, and migration. These Gal-3-mediated effects result from a
selective binding to K-Ras.GTP, causing increased nanoclustering in the cell membrane and leading to robust Ras signaling.
Regulation of the interactions between Gal-3 and active K-Ras is not fully understood.
Methods and Findings: To gain a better understanding of what regulates the critical interactions between these two
proteins, we examined the role of Gal-3 in the regulation of K-Ras by using Gal-3-knockout mouse embryonic-fibroblasts
(Gal-3
-/- MEFs) and/or Gal-3/Gal-1 double-knockout MEFs. We found that knockout of Gal-3 induced strong downregulation
(,60%) of K-Ras and K-Ras.GTP. The downregulation was somewhat more marked in the double-knockout MEFs, in which
we also detected robust inhibition(,50%) of ERK and Akt activation. These additional effects are probably attributable to
inhibition of the weak interactions of K-Ras.GTP with Gal-1. Re-expression of Gal-3 reversed the phenotype of the Gal-3
-/-
MEFs and dramatically reduced the disappearance of K-Ras in the presence of cycloheximide to the levels seen in wild-type
MEFs. Furthermore, phosphorylation of Gal-3 by casein kinase-1 (CK-1) induced translocation of Gal-3 from the nucleus to
the cytoplasm and the plasma membrane, leading to K-Ras stabilization accompanied by downregulation of the tumor
suppressor miRNA let-7c, known to negatively control K-Ras transcription.
Conclusions: Our results suggest a novel cross-talk between Gal-3-mediated downregulation of let 7c microRNA (which in
turn negatively regulates K-Ras transcription) and elucidates the association among Gal-3 let-7c and K-Ras transcription/
translation, cellular compartmentalization and activity.
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Introduction
MicroRNAs (miRNAs) are small, noncoding RNAs that
regulate gene expression by repressing transcription or degrada-
tion of the target mRNA [1]. In cancer cells, miRNAs can regulate
tumor development by functioning as tumor suppressors or as
oncogenes [2]. Ras genes and oncogenes are regulated by
members of the let-7 miRNA family by virtue of the possession
by these genes of let-7 complementary sites in their 39-untranslated
regions (UTRs) [3]. Reduction of let-7 has been reported in several
human cancers including melanoma, colon and lung [4–6] and
their expression has been shown to attenuate cancer cell
proliferation and tumorigenicity [7,8]. Recently a single-nucleo-
tide polymorphism (SNP) was detected in a let-7 miRNA
complementary site in the KRAS 39UTR in non-small cell lung
carcinoma (NSCLC) and was found to be correlated with
increased risk for NSCLC [9]. In normal cells, let-7 miRNAs act
as tumor-suppressor genes that downregulate Ras expression [2].
Here we examined the possibility that Galectin-3 (Gal-3) interacts
with active K-Ras [10,11] and may modulate let-7 expression.
Gal-3 is a b-galactoside-binding protein that contains a COOH-
terminal carbohydrate recognition/binding domain and an NH2-
terminal proline- and glycine-rich domain [12]. Gal-3 is highly
expressed in a number of human malignances and has been shown
to stimulate cellular proliferation, anchorage-independent cell
growth, and inhibition of apoptosis via K-Ras-mediated Raf/
MEK/ERK activation [10].
K-Ras is the most frequently mutated of the Ras genes (H-, N-
and K-Ras) in human cancers [13,14]. The proteins encoded by
Ras genes are key players in development and in carcinogenic
processes and tumor maintenance. They are guanine nucleotide-
binding proteins that act as binary molecular switches on the inner
plasma membrane and on intracellular membranes. In response to
activation by growth-factor receptors, Ras proteins are activated
by guanine nucleotide exchange factors (GEFs) that stimulate
GDP/GTP exchange. Ras guanine nucleotide-activating proteins
(RasGAPs) contribute to GTP hydrolysis by Ras. In the active
(GTP-bound) state, Ras proteins recruit downstream effectors
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activate a multitude of effectors including Raf, phosphatidylino-
sitol-3-OH kinase (PI3-K), and Ral-GEFs, which together regulate
cell proliferation, differentiation, survival, and death. Oncogenic
Ras proteins are insensitive to RasGAPs and are therefore
constitutively active [15–17].
We have previously shown that K-Ras gains some of its
important oncogenic properties by interaction with Gal-3, which
acts as a selective intracellular scaffold of K-Ras.GTP [10,11].
Such interaction stabilizes K-Ras in its active (GTP-bound) state
as if it is constitutively active oncogenic K-Ras [10,11]. It also
strengthens the binding of K-Ras.GTP to the cell membrane,
increases its nanoclustering in the membrane, and enhances its
robust signaling [18]. Other groups as well as ours have found a
close correlation between Gal-3 expression, malignancy, tumori-
genicity and K-Ras.GTP, specifically; high cellular Gal-3 protein
expression results in K-Ras GTP loading [19], and for this
interaction to occur, Gal-3 must be translocated from the nucleus
to the cytoplasm [20]. The Gal-3 translocation is regulated by its
phosphorylation catalyzed by casein kinase 1 (CK1) [21,22]. This
phosphorylation promotes the nucleus-to-cytosol translocation
[20] and hence the retention/stability of K-Ras.GTP in the
plasma membrane. Loss of nuclear Gal-3 expression is associated
with tumor progression [20], just as loss of let-7 leads to
progression of many human tumors [23]. These findings led us
to postulate that loss of Gal-3 might be related to the increase in
let-7 and decrease in K-Ras stability.
Here we used Gal-3-knockout mouse embryonic fibroblasts
(MEFs) and CK1 inhibitors to demonstrate a newly identified dual
regulatory mode of K-Ras. The results indicate that Gal-3
negatively regulates let-7 expression, which in turn leads to
increased expression of K-Ras. We further report that Gal-3
phosphorylation is regulated by CK1, which stabilizes the
membrane activity of activated K-Ras protein.
Materials and Methods
Transgenic Gal-1-Knockout (Gal-1
-/-), Gal-3-Knockout
(Gal-3
-/-) and Gal-1/Gal-3 Double-Knockout (Gal-1
-/-/Gal-
3
-/-) Mice and Preparation of Primary Mouse Embryonic
Fibroblasts
Wild-type (wt), Gal-1-knockout (Gal-1
-/-), Gal-3-knockout (Gal-
3
-/-) and Gal-1/Gal-3 double-knockout (Gal-1
-/-/Gal-3
-/-) mice,
all with an sv/129 background, were prepared as described before
[24–26]. MEFs from the wild-type and from each of the mutants
were prepared, characterized, and immortalized as described [27].
Gal-3
-/- cells stably expressing Gal-3 or the vector only were
established by infection of human Gal-3 in pBABE vector, or in
the vector alone, with Phoenix 2
TM Ampho 293, a gift from Dr.
Valery Krizhanovsky (Weizmann Institute, Rehovot, Israel). Cells
were selected in the presence of puromycin (2 mg/ml) and were
maintained in complete DMEM containing puromycin (2 mg/ml).
An enhanced chemiluminescence (ECL) kit was purchased from
Amersham Pharmacia Biotech, Hoechst 33258 from Sigma-
Aldrich, cycloheximide (CHX) and the casein kinase inhibitors
CKI-7 and CKI D4476 from Sigma and Mercury, respectively.
Mouse anti-pan-Ras (Ab-3) and mouse monoclonal anti-K-Ras
antibodies (mAbs) were obtained from Calbiochem, rabbit anti-b-
tubulin antibodies (Abs) from Santa Cruz Biotechnology, mouse
anti-phospho-ERK Ab from Sigma-Aldrich, and rabbit anti-
phospho-Akt (ser473) and rabbit anti-glyceraldehyde-3-phosphate
dehydrogenase (14C10) Abs from Cell Signaling Technology.
Peroxidase-conjugated goat anti-mouse IgG, peroxidase-conjugat-
ed goat anti-rat IgG, and peroxidase-conjugated goat anti-rabbit
IgG were from Jackson ImmunoResearch Laboratories.
Western Blotting
Cells were washed with phosphate-buffered saline (PBS) and
lysed with lysis buffer A (50 mM Tris–HCl pH 7.6, 20 mM
MgCl2, 200 mM NaCl, 0.5% IgepalH CA-630 (Sigma), 1 mM
DTT, and antiproteases). Lysates were subjected to polyacryl-
amide gel electrophoresis (PAGE) in the presence of sodium
dodecyl sulfate (SDS), followed by immunoblotting with one of the
following Abs: pan-Ras 1:2,500, anti-K-Ras 1:50, anti-b-tubulin
1:1000, anti-Gal-3 1:1000, anti-phospho-ERK 1:10,000, and anti-
ERK 1:2,000. Immunoblots were then exposed to peroxidase-
conjugated goat anti-mouse IgG, peroxidase-conjugated goat anti-
rabbit IgG, or peroxidase-conjugated goat anti-rat IgG (all at
1:2500), and protein bands were visualized with the ECL kit.
Protein bands were quantified by densitometry with the Image
EZQuant-Gel software (EZQuant).
Ras.GTP Assays
Lysates containing 1 mg protein were used for determination of
Ras.GTP by the glutathione S-transferase–Ras-binding domain of
Raf (GST-RBD) pull-down assay as described [19], followed by
western blotting with Ras isoform-specific Abs as described above.
Stimulation by Epidermal Growth Factor
Cells were serum-starved for 24 h after plating and then
stimulated for 5 min with 100 ng/ml epidermal growth factor
(EGF). The cells were then lysed and their Ras.GTP content was
determined by the GST-RBD pull-down assay.
Confocal Microscopy
Cells (1.5610
5) were plated on glass coverslips and treated for
24 h with 60 mM D4476 or the vehicle (control; 0.1% DMSO).
Cells were fixed and then permeabilized with 0.5% Triton X-100.
Samples were blocked for 30 min with 2% bovine serum albumin
and 200 mg/ml goat gamma globulin. Cells were labeled for 1 h
with 1 mg/ml rat anti-Gal-3 or anti-pan-Ras Abs, and then with
1:750 goat anti-rat fluorescein or donkey anti-mouse cy3 Abs
(Jackson), respectively. Each incubation was followed by three
thorough washes. Staining intensity was analyzed with a Zeiss
LSM 510 META confocal microscope. Fluorescence intensity was
quantified by ImageJ software as previously described [19].
Cell Transfection
Wild-type and Gal-3
-/- MEFs were transfected with 2 mgo f
plasmid DNA coding for green fluorescent protein pEGFP-K-Ras
and pEGFP-H-Ras (G12V), as described [28,29]. This plasmid
was transfected into MEFs using the Lipofectamin reagent
(Invitrogen) according to the manufacturer’s instructions. GFP
intensity was monitored with a Zeiss LSM META510 confocal
microscope. Data from control experiments with red fluorescent
protein (RFP) transfections of wt, Gal-1
-/- and Gal-3
-/- MEFs
indicated that the transfection efficiency in all MEFs was similar
(25%65%, n=24).
RNA Purification
Total RNA was isolated from cultured cells using the protocols
and reagents of the mirVana
TM miRNA Isolation Kit (Ambion).
Concentrations of RNA samples were determined by measure-
ment of their absorbance at 260 nm (A260) in a spectrophotom-
eter. Purified RNA was stored at 270uC in RNase-free water and
subsequently used for real-time (RT) –PCR.
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Extracts of total RNA (1 mg) were reverse-transcribed in a total
volume of 20 ml using the Verso
TM RT–PCR Kit (Thermo
Scientific) according to the manufacturer’s instructions. cDNA
samples (1 mg) were used for RT–PCR (QPCR SYBRH Green
Mix Plus ROX Vial; ABgene). The primers employed targeted K-
Ras and H-Ras genes and the housekeeping gene B2M. The
relative mRNA expression of the target gene was normalized to
the expression of the B2M reference gene.
Quantitative RT-PCR for MicroRNA Analysis
Quantitative miRNA levels were determined by RT–PCR with
the 7900 HT Sequence Detection System (Applied Biosystems)
and TaqManH Gene Expression Assay (Applied Biosystems) for
hsa-let-7a (assay ID 377), hsa-let-7c (assay ID 379), and as an
endogenous control, U6 snRNA (assay ID 1973). In each assay,
total RNA (10 ng) was subjected to reverse transcription with
TaqManH Universal PCR Master Mix No. AmpEraseH and the
relevant TaqManH reagents for target genes. RT–PCR was
carried out in 20 ml of reaction mixture according to the
manufacture’s protocol. Amplification was carried out as follows:
10 min at 95uC, 40 cycles at 95uC for 15 s, and 1 cycle at 60uC for
60 s. The relative mRNA expression was normalized to the
expression of U6 snRNA in each sample.
Statistical Analysis
Data are expressed as means 6 SEM. Significant differences in
mean values were assessed by one-way ANOVA followed by
Tukey’s post-hoc test or Student’s t-test. A value of p#0.05 was
considered significant.
Results
Gal-1
-/-, Gal-3
-/-, and Gal-1
-/-/Gal-3
-/- MEFs Express Low
Levels of Ras.GTP
Knockout mice were prepared and characterized as described
previously [24–26]. The MEFs were immortalized with SV40 to
create stable cell lines (see Methods). We pooled the distinct MEF
cell lines of each of the Galectin-knockout mice and examined
them for the presence or absence of Gal-1 and Gal-3 by western
blotting. All of the selected cell colonies exhibited the expected
Galectin phenotype (Figure 1A). Gal-1 protein could not be
detected in the Gal-1
-/- MEFs, Gal-3 protein could not be detected
in Gal-3
-/- MEFs, and neither Gal-1 nor Gal-3 protein was
detectable in Gal-1
-/-/Gal-3
-/- MEFs (Figure 1A).
Gal-1 acts as a selective binding partner of H-Ras.GTP and can
also weakly bind K-Ras.GTP (achieving about 5% of its binding to
H-Ras.GTP) [30]. Gal-3, however, is a selective binding partner of
K-Ras.GTP [11]. Using the Ras-binding domain of Raf (Raf-
RBD) pull-down assay and pan-Ras Abs we found, in agreement
with previous results, that each of the Galectin-knockout MEFs
expressed significantly lower levels of Ras.GTP than those of the
wt MEFs (Figure 1A): Ras.GTP levels were indeed very low in the
Gal-3
-/-, the Gal-1
-/-, and the double-knockout MEFs as
compared with the wild type (Figure 1A). Statistical analysis
suggested that in Gal-3
-/- cells total Ras was reduced, relative to
the wild type MEFs, by 40%61%, (n=3), total K-Ras by
38%61.8% (n=3), and K-Ras.GTP by 66%66.8% (n=3). We
concluded that in the absence of Gal-3, levels of K-Ras and K-
Ras.GTP are lower than in wt MEFs. It seems, however, that the
reduction in K-Ras.GTP was greater than the reduction in total
K-Ras. This may reflect somechanges in the expression levels of
Ras-exchange-factors or Ras GTPase activating proteins.
Because of the poor response of the H-Ras Abs in western
blotting, H-Ras.GTP levels were determined directly by confocal
microscopy (Figure 2). These results, consistently with earlier
studies [11,30], implied that the Gal-1 protein stabilizes and is
highly specific for H-Ras.GTP protein (Figure 2B), and that Gal-3
stabilizes and is highly specific for K-Ras.GTP protein (Figure 1
and 2B). N-Ras levels were low, and were similar in all cell lines
examined (not shown). These results, which represent the first
direct demonstration of the cellular behavior of H-Ras and K-Ras
proteins in Galectin-knockout cells, provide a unique and powerful
cellular system for studying the interactions of Gal-3 and K-Ras
during cancer progression.
Using specific K-Ras Abs we found that K-Ras.GTP protein
was much lower in the Gal-3
-/- MEFs than in the Gal-1
-/- or the
wt MEFs (Figure 1A), further supporting a selective interaction
between Gal-3 and K-Ras.GTP. Similarly, we found a significant
decrease in Ras.GTP protein in the Gal-1
-/- MEFs (Figure 1A, B)
in the presence or absence of serum (respectively 30% or 34%
percent of wt). These findings suggested that H-Ras.GTP is
downregulated in the Gal-1
-/- cells, since with K-Ras.GTP protein
the observed difference relative to the wild type was not significant
(Figure 1A, B). Levels of the downstream Ras effectors (phospho-
ERK and phospho-Akt proteins) in Gal-3
-/- and Gal-1
-/- MEFs
determined in the presence of serum were similar to those of the
wild type (Figure 1A, B). In Gal-3
-/- MEFs grown in the absence of
serum, however, both phospho-ERK and phospho-Akt were
reduced relative to wild type (Figure 1B, ,20%). There were no
detectable differences between phospho-ERK or phospho-Akt in
Gal-1
-/- and control MEFs. In the Gal-1
-/-/Gal-3
-/- double-
knockout MEFs, however, both of these phosphorylated enzymes
were significantly decreased relative to all the other MEFs (by
50%, see statistical analysis in Figure 1A, B middle panels). These
results suggested that in Gal-1
-/- MEFs, Gal-3 compensates for
Gal-1 and can activate downstream signals to ERK and Akt.
The above results were corroborated by experiments in which
the protein levels of Ras, phospho-ERK and phospho-Akt were
examined in our MEF lines following stimulation by EGF
(Figure 1B). These experiments were done under conditions of
serum starvation followed by induction for 5 min with 100 nM
EGF (Figure 1B). We found that EGF induced a significant
increase in Ras.GTP protein in the wt MEFs (Figure 1B), while the
Gal-1
-/-, Gal-3
-/-, and double-knockout MEFs were only weakly
stimulated by comparison (Figure 1B). Similar results were
obtained for phospho-ERK and phospho-Akt proteins in the
EGF-stimulated MEFs (Figure 1B). These findings strongly
suggested that Gal-3 and Gal-1 interact respectively with K-
Ras.GTP and H-Ras.GTP and stabilize these GTP-bound Ras
proteins, with some overlap between Gal-3 and Gal-1 (where Gal-
1 can stabilize H-Ras.GTP and to some extent also K-Ras.GTP,
whereas Gal-3 stabilizes only K-Ras.GTP).
Gal-3 Mediates K-Ras Localization and Gal-1 Mediates H-
Ras Localization in Cell Membranes
Previous data have shown that K-Ras protein is localized
mainly to the plasma membrane and that Gal-3 stabilizes this
localization while inducing K-Ras.GTP nanoclustering [18]. In
support of these results, our findings on fluorescent confocal
microscopy confirmed that K-Ras was localized mainly to the
plasma membrane in both the wt and the Gal-1
-/- MEFs
(Figure 2A) and that plasma membrane localization could not be
detected in the Gal-3
-/- MEFs (Figure 2A). Similarly, Gal-1
stabilizes H-Ras.GTP in the cell membrane (Figure 2B). Note that
the background fluorescence of untransfected cells was barely
detectable (Figure 2C).
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with previous reports, and raise important questions concerning
the control of K-Ras biology by Gal-3. These include questions
about the way in which Gal-3 controls K-Ras stability and
whether such control is determined at the level of protein–protein
interactions only or also at the transcriptional level. Also of interest
is whether phosphorylation of Gal-3 [20] affects its interactions
with K-Ras, and if so, in what way.
Gal-3 Attenuates K-Ras Protein Degradation
To further investigate the effects of Gal-3 on K-Ras protein
stability and localization, we examined the rate of K-Ras protein
degradation in Gal-3
-/- and in wt MEFs following their exposure
to 50 mg/ml CHX, a protein synthesis inhibitor. Cells were serum
starved at 37uC for 12 h and then treated at zero time with CHX
and lysed at the indicated times (Figure 3). Ras protein levels in the
lysates were detected with specific anti-K-Ras Abs. Whereas K-
Figure 1. Gal-1- and Gal-3-knockout and Gal-1/Gal-3 double-knockout mouse embryonic fibroblasts express low levels of Ras.GTP.
Gal-1
-/-, Gal-3
-/-, Gal-1
-/-/Gal-3
-/-, and wild-type (wt) MEFs were homogenized as described in Methods. Expression levels of Gal-1, Gal-3, Ras.GTP, total
Ras, K-Ras.GTP, total K-Ras, and the Ras downstream effectors ERK, phospho-ERK, Akt, and phospho-Akt were determined in aliquots of the
homogenates by SDS–PAGE followed by immunoblotting with the relevant specific antibodies, as described in Methods. b-Tubulin served as a
loading control. Shown are typical immunoblots visualized by ECL. A. MEFs were grown in medium containing 10% fetal calf serum (FCS). B. MEFs
were grown in medium containing 0.5% FCS, and then stimulated for 5 min by 100 nM EGF. Upper panels in A and B represent typical immunoblots
representing expression levels of Gal-1, Gal-3, Ras.GTP, Total Ras, K-Ras.GTP, Total K-Ras, b-tubulin, phospho-ERK, Total ERK, phospho-Akt and Total
Akt in wt, Gal-1
-/-, Gal-3
-/-, and Gal-1
-/-/Gal-3
-/- MEFs. Statistical analysis of the levels of Ras.GTP, K-Ras.GTP, phospho-ERK and phospho-Akt in the
different MEF genotypesis shown in the histograms of the middle panels (means 6 SEM, n=3 *p,0.05, **p,0.001). Genotypes are marked by colors
of the columns for wt (black), Gal-1
-/- (dark gray), Gal-3
-/- (light gray) and Gal-1
-/-/Gal-3
-/- (white). Lower panel in A shows histograms of Total Ras and
Total K-Ras levels in wild type and in Gal-3
-/- MEFs (means 6 SEM, n=3). AU, arbitrary units; MEFs, mouse embryonic fibroblasts; wt, wild type.
doi:10.1371/journal.pone.0027490.g001
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the wt MEFs, they were significantly reduced (by 40% at 8 h) in
the Gal-3
-/- MEFs. Representative immunoblots are presented in
Figure 3A (left panel shows immunoblots; right panel shows
statistical analysis). Consistently with these results we found that
Gal-3 enhanced K-Ras stability in Gal-3
-/- cells that were infected
with Gal-3 (Gal-3
-/-/pBABE-Gal-3), but not in cells infected with
the empty vector only (Gal-3
-/-/pBABE) (Figure 3B; upper panel
shows typical immunoblots, lower panel shows statistical analysis).
We can thus conclude that the previously described correlation
between Gal-3 expression and K-Ras.GTP in human tumor cells
[10,11,19] is due in part to the stabilization of active Ras protein
by Gal-3.
Gal-3 Phosphorylation Mediates K-Ras Membrane
Localization
We then turned our attention to the role of Gal-3 serine
phosphorylation [21] in K-Ras protein cellular localization. Using
wt MEFs in the presence and in the absence of the CK1 inhibitor
D4476 [31], we stained the cells with anti-Gal-3 Abs (green
fluorescence), with anti-Ras Abs (red fluorescence), or-to label the
nuclei)-with Hoechst (purple fluorescence) (Figure 4A). We used
the inhibitors D4476 and CKI-7 alternatively and obtained similar
results with both. Confocal fluorescence images obtained from the
untreated MEFs revealed that Ras was localized mainly to the cell
membrane (Figure 4Ai). Following D4476 treatment, however, a
major fraction of Ras protein was mislocalized into the cytoplasm
(Figure 4Aii). A similar pattern of Ras protein localization was
observed in Gal-3
-/- MEFs (Figure 4Aiii). These findings supported
the notion that Gal-3 regulates K-Ras protein localization into the
plasma membrane. Notably, unlike in the untreated cells, Gal-3
protein in the D4476-treated MEFs was localized mainly to the
nuclei (Figure 4Aiv, 4Av). This indicated that, as expected,
phosphorylation of Gal-3 prevents translocation of this protein
from the nucleus [20], and that D4476 treatment does not affect
the nuclear structure (Figure 4Avii-ix). Merged images (Figure 4Ax-
xii) demonstrated overlapping of Gal-3 and K-Ras in the plasma
membrane (Figure 4Ax), marked mislocalization of K-Ras and
pronounced nuclear localization of Gal-3 in the D4476-treated
cells (Figure 4Axi), and lack of Gal-3 staining or Ras mislocaliza-
Figure 2. Gal-3 Mediates K-Ras Localization and Gal-1 Mediates H-Ras Localization in Cell Membranes. A. Gal-3 mediates K-Ras
localization in the cell membrane. Selective mislocalization of GFP-K-Ras (12V) in Gal-3
-/- MEFs but not in wt or Gal-1
-/- MEFs. Cells were transfected
with pEGFP-K-Ras (G12V) and were fixed after 48 h as described in Methods. Typical fluorescent confocal images of cultured cells of wt (upper panel)
and of Gal-3
-/- (lower panel) MEFs are shown. Bar, 5 mm. Data are presented as the mean fluorescence intensity of GFP-K-Ras (12V) in the plasma
membrane (means 6 SEM, N=52 cells; wt, n=12; Gal-1
-/-, n=14; and Gal-3
-/-, n=26, **p,0.001, ANOVA). B. Gal-1 mediates H-Ras localization in the
cell membrane. Selective mislocalization of GFP-H-Ras (12V) in Gal-1
-/- MEFs but not in wt MEFs. Experimental details are as in A except that pEGFP-H-
Ras (G12V)-transfected Gal-1
-/- MEFs were used. Means 6 SEM are shown (wt, n=14; Gal-1
-/-, n=12, **p,0.001, t-test). C. Typical background image
of untransfected Gal-3
-/- cells (1 of 3 MEFs examined). Similar images were obtained with the other cell lines used. MEFs, mouse embryonic fibroblasts;
wt, wild type.
doi:10.1371/journal.pone.0027490.g002
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-/- MEFs (Figure 4Axii). To verify that the effect
on Ras was not caused by autofluorescence or by nonspecific
staining of the MEFs, we stained wt and Gal-3
-/- MEFs with an
irrelevant first Ab (rat anti-Gal-3 Ab) followed by cy3-labeled
donkey anti-mouse (red). No autofluorescence or nonspecific
staining of the MEFs was observed (Figure S1). Finally, because we
know from earlier reports that of all the Ras isoforms only K-Ras
interacts with Gal-3 [10,11,19], we assume that D4476 disrupted
the localization of this isoform and not of the other isoforms from
the plasma membranes (Figure 4A). Using K-Ras-specific Ab we
found that a CK1 inhibitor indeed caused a significant decrease in
K-Ras.GTP in the drug-treated wt MEFs (Figure 4B). As
expected, no such effect was observed in the Gal-3
-/- MEFs
(Figure 4B).
Transcriptional Control of K-Ras by let-7c
Ras transcription is negatively regulated by the let-7 miRNA
family of small RNAs [3]. To determine whether this negative
regulation might be associated with the positive regulation of K-
Ras by Gal-3, we first examined a possible correlation in the Gal-
3
-/- cells between the levels of K-Ras transcripts and let-7
transcripts, particularly let-7a and let-7c (the abundant miRNAs
of the let7 family). Transcripts of let-7a and let-7c, as well as of K-
Ras, were determined by RT–PCR in wt and in Gal-3
-/- MEFs
(Figure 5). We also determined the levels of the H-Ras transcript as
a control for specificity. Our results showed that let-7c levels were
significantly higher in the Gal-3
-/- MEFs than in the control wt
MEFs (Figure 5A; 2.160.6-fold higher). This correlated well with
the observed reduction in expression level of K-Ras in the Gal-3
-/-
MEFs (Figure 5A). Stable expression of Gal-3 in Gal-3
-/- cells
reversed these phenomena (Figure 5B). Importantly, the negative
impact of let-7c on K-Ras expression was specific to this isoform, as
indicated by its lack of detectable effect on H-Ras transcript levels
in the wt or in the Gal-3
-/- MEFs (Figure 5A, B). Expression of
Gal-3 in the Gal-3
-/- MEFs was accompanied by a marked
increase in K-Ras.GTP (3.1960.5 fold increase) (Figure 5C).
The above results suggest that Gal-3 regulates the transcrip-
tional level of let-7, and show for the first time that Gal-3 mediates
K-Ras transcription through let-7c.
Discussion
Gal-3-knockout MEFs (Figure 1) and CK1 inhibitors (Figure 4)
were used in this study to demonstrate, first, a novel dual mode of
regulation by Gal-3 of K-Ras expression and cellular localization.
Gal-3
-/-. The MEFs exhibited low levels of K-Ras.GTP and Ras in
Figure 3. Gal-3 attenuates K-Ras protein degradation. A.
Attenuation of K-Ras degradation in wt and Gal-3
-/- MEFs. Cells of the
wt and Gal-3
-/- MEFs were grown (2610
5 cells per 6-cm plate) in the
presence of 10% FCS, which was replaced 24 h later by 0.5% FCS. Cells
were treated with cycloheximide (CHX; 50 mg/ml) and then harvested at
zero time (control) and at 2.5, 6, and 8 h after CHX treatment. K-Ras in
the lysates was quantified by SDS–PAGE followed by immunoblotting
with anti-K-Ras Abs. b-Tubulin served as a loading control. Upper panel:
typical immunoblots visualized by ECL. Lower panel: expression levels
of K-Ras, normalized to b-tubulin as a percentage of the expression at
zero time (means 6 SEM, n=3 *p,0.05). B. Attenuation of K-Ras
degradation in Gal-3
-/- vector-infected and Gal-3
-/- pBABE-infected
MEFs. Stable cell lines (see Methods) were treated with CHX and then
harvested and immunoblotted as in A. Upper panel: typical immuno-
blots visualized by ECL. Lower panel: expression levels of K-Ras,
normalized to b-tubulin as a percentage of the expression at zero time
(means 6 SEM, n=3 *p,0.05). MEFs, mouse embryonic fibroblasts; wt,
wild type.
doi:10.1371/journal.pone.0027490.g003
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27490Figure 4. Inhibition of Gal-3 phosphorylation mediates K-Ras membrane mislocalization and downregulation. A. The casein kinase
inhibitor D4476 disrupts K-Ras localization in the cell membranes and attenuates export of Gal-3 from the nuclei of wt MEFs. Cells were plated on
glass coverslips and treated for 24 h with D4476 or vehicle (control) as described in Methods. The cells were then fixed and labeled with Hoechst
(purple), mouse anti-pan-Ras Ab followed by cy3-labeled donkey anti-mouse (red), and rat anti-Gal-3 Abs followed by fluorescein-labeled goat anti-
rat Ab (green). Gal-3
-/- MEFs served as a reference control. Upper panel: typical images, including triple-fluorescence merged images. Lower panel: (i)
mean fluorescence intensity of fluorescein in the nuclei and (ii) of cy3 in the membrane (means 6 SEM, n=55 cells, **p,0.001). B. The casein kinase
inhibitor CKI-7 reduces K-Ras.GTP expression in wt MEFs but not in Gal-3
-/- MEFs. Cells from wt and from Gal-3
-/- MEFs were grown in a 10-cm dish,
treated for 24 h with 75 mM CKI-7 or vehicle (control), and then lysed. Lysates were subjected to quantification of active K-Ras.GTP, total K-Ras and
Gal-3 by SDS–PAGE followed by immunoblotting with K-Ras and Gal-3 Abs as described in Methods. b-Tubulin served as a loading control. Left panel:
typical immunoblots visualized by ECL. Right panel: levels of K-Ras.GTP expression. AU, arbitrary units; wt, wild type.
doi:10.1371/journal.pone.0027490.g004
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these findings, demonstrating mislocalization of GFP-K-Ras
(G12V) from the plasma membrane to the cytosol in Gal-3
-/-
MEFs (Figure 2).
We found that K-Ras degradation was reduced by Gal-3
(Figure 3). This suggested that Gal-3 might protect K-Ras.GTP
from degradation through their specific interactions [11,18]. The
suggestion is in accord with earlier studies showing that cytosolic
levels of Gal-3 determine the magnitudes of K-Ras.GTP
nanoclustering and K-Ras signal output [18]. The b-sheet layers
of the Gal-3 carbohydrate-recognition domain contain a hydro-
phobic pocket that may accommodate the farnesyl group of K-
Ras. Introducing V125A substitution within this hydrophobic
pocket has been shown to yield a dominant negative mutant that
inhibits K-Ras activity [18]. Similarly, the lack of Gal-3, as
described here, evidently caused destabilization of K-Ras and
hence its more rapid degradation, leading to lower amounts of K-
Ras in the cells (Figure 3).
Secondly, we showed that Gal-3 phosphorylation by CK1
affects the stabilization of active K-Ras protein and its activity in
the cell membrane (Figure 4). We found that Gal-3 negatively
regulates expression of the miRNA let-7, which itself down-
regulates K-Ras expression [3] (Figure 5). Thus, removal of Gal-3
leads to a decrease in expression of K-Ras (Figure 1) and vice
versa. In the latter case, as in many human tumors, Gal-3 acts as a
negative regulator of let-7 expression, leading to an increase in K-
Ras expression levels associated with increased stability and
activity of K-Ras.GTP. This dual mode of regulation of K-Ras by
Gal-3/let-7 suggests a new signaling pathway (see scheme in
Figure 6).
When we examined the prominent Ras downstream effectors
ERK and Akt we found no significant differences between the Gal-
1
-/- and the wt MEFs (Figure 1). By contrast, the levels of both
pERK and pAkt in the Gal-3
-/- MEFs (,20% lower than wt
MEFs) and in the Gal-1
-/-/Gal-3
-/-MEFs were significantly lower
relative to the wt than in all other MEFs (5068%, p,0.05,
Figure 1A, B). These results suggest that Gal-3 might compensate
for Gal-1, and that it can activate downstream signals to ERK and
Akt. In the absence of Gal-3, the signal from Gal-1-H-Ras.GTP
[30] and some signals from Gal-1-K-Ras.GTP [11] are probably
sufficient for some activation of the downstream signals but not for
full activation of the signals.
We also showed here for the first time that phosphorylation of
Gal-3, which occurs on serine 6 by CK1 [21,22] promotes its
translocation from the nucleus to the cytoplasm [20] and enhances
its association with K-Ras.GTP (Figure 4). Thus, CK1 specific
inhibitors induced mislocalization of K-Ras (Figure 4). These
results are consistent with early reports that a Gal-3 mutant which
was not phosphorylated (S6A) and was not exported from the
nucleus did not protect BT cancer cell lines from drug-induced
apoptosis [32,33]. It is possible that CK1 phosphorylation of Gal-3
might modulate the anti-apoptotic effects of K-Ras [34] and Gal-3
[33,35].
Control of K-Ras expression by the let-7 family of miRNAs has
been well documented. The significance of this control mechanism
has been highlighted in a number of studies that report a
correlation between let-7 expression and cancer. Low levels of let-
7 expression in human tumors correlate with high levels of K-Ras
[36–38]. Binding of let-7 to the K-Ras 39-untranslated region in the
let-7 miRNA complementary site (K-Ras-LCS6) results in a
Figure 5. Control of K-Ras transcription and expression by Gal-
3 via let-7c. The relative amounts of let-7a and let-7c miRNAs and of K-
Ras and H-Ras transcripts were determined in: (A) Gal-3
-/- and wt MEFs;
(B) Gal-3
-/- MEFs re-expressing Gal-3 (Gal-3
-/-/pBABE-Gal-3) and Gal-3
-/-
MEFs expressing pBABE only. Quantities of the miRNA were normalized
to U6 snRNA levels, while the quantities of H-Ras and K-Ras transcripts
determined by RT-PCR were normalized to levels of the endogenous
housekeeping gene B2M (n=6, *p,0.05, **p,0.001). C. Immunoblots
of Gal-3, K-Ras total and K-Ras.GTP from wt, Gal-3
-/-/pBABE and Gal-3
-/-/
pBABE-Gal-3 MEFs. Cells were homogenized and expression levels of K-
Ras.GTP, total K-Ras, and Gal-3 were determined in aliquots of the cell
homogenates by SDS-PAGE followed by immunoblotting with the
relevant specific antibodies (see Methods). b-Tubulin served as a
loading control. Left panel, typical immunoblots visualized by ECL.
Right panel, levels of K-Ras.GTP expression (means 6 SEM, n=3,
**p,0.001). AU, arbitrary units; wt, wild type.
doi:10.1371/journal.pone.0027490.g005
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[36], with consequent reduction in K-Ras expression. A variant
allele in the K-Ras 3-untranslated region, which arises in the let-7
miRNA complementary site (K-Ras-LCS6) and leads to increased
K-Ras expression in lung cancer [36], was shown to significantly
reduce survival time in squamous cell carcinoma of the head and
neck, suggesting that this variant may alter the phenotype or
therapeutic response of the disease [37]. In another study, genetic
modulation of the let-7 miRNA binding to the KRAS 39-
untranslated region was found to correlate with survival of
metastatic colorectal cancer patients who underwent salvage
cetuximab-irinotecan therapy [38]. Yet another study described
a SNP in a let-7 miRNA in the complementary site in the KRAS 39-
untranslated region that reduces the binding of let-7 and correlates
with increased risk of NSCLC [9]. Our results showing that Gal-3,
through its negative regulation over let-7, is highly carcinogenic
are consistent with that study. However, the dual control over K-
Ras expression and activity that we describe here indicates that let-
7, even without oncogenic mutation, can regulate Ras activity and
that this might be a general phenomenon related to the
interactions between tumor suppressor genes (e.g. let-7) and
proto-oncogenes (e.g. K-Ras) or oncogenes (e.g. K-Ras G12V or
G12D). The possibility of upregulation of tumor suppressor(s)
along with epigenetic downregulation of proto-oncogenes is an
interesting phenomenon and should be studied in future research.
Supporting Information
Figure S1 Autofluorescence in wt and in Gal-3
2/2
MEFs. MEFs were plated on glass coverslips as described in
Methods. They were then fixed and labeled with Hoechst (purple).
To verify that the effect on Ras was not caused by autofluores-
cence or by nonspecific staining of the MEFs, we stained wt and
Gal-3
-/- MEFs with an irrelevant first Ab (rat anti-Gal-3 Ab)
followed by cy3-labeled donkey anti-mouse (red). No autofluores-
cence or nonspecific staining of the MEFs was observed.
(TIF)
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